Treatment and prevention of Gardnerella vaginalis infections
AssigneeThe Trustees of Columbia University in the City of New York
InventorAdam J. Ratner
Life of this patent
Estimating the term…
Abstract
The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (VLY) toxin from Gardnerella vaginalis, and biologically active fragments and variants thereof. The invention is also directed to anti-VLY antibodies and to their use therapeutically and in a new ELISA assay of VLY toxin. Other embodiments of the invention are directed to VLY toxoids and to vaccines that use the new VLY toxoids as immunogens.
Claims13
An isolated and purified pore-forming toxoid of vaginolysin from G. vaginalis, which toxoid differs from vaginolysin identified by SEQ ID NO:
- 2 by a single amino acid substitution consisting of a tryptophan residue at position 480, or an immunologically active fragment thereof comprising the single amino acid substitution.
An isolated and purified pore-forming toxoid of vaginolysin from G. vaginalis, which toxoid differs from vaginolysin identified by SEQ ID NO:
- 2 by a single amino acid substitution consisting of an isoleucine residue at position 500, or an immunologically active fragment thereof comprising the single amino acid substitution.
An isolated and purified pore-forming toxoid of vaginolysin from G. vaginalis, which toxoid differs from vaginolysin identified by SEQ ID NO:
- 2 by a single amino acid substitution consisting of an arginine [R] at position 471, or an immunologically active fragment thereof comprising the single amino acid substitution.
An isolated and purified pore-forming toxoid of vaginolysin from G. vaginalis, which toxoid differs from vaginolysin identified by SEQ ID NO:
- 2 by a single amino acid substitution consisting of a cysteine [C] at position 473, or an immunologically active fragment thereof comprising the single amino acid substitution.
An isolated and purified pore-forming toxoid of vaginolysin from G. vaginalis, which toxoid differs from vaginolysin identified by SEQ ID NO:
- 2 by two amino acid substitutions consisting of an arginine [R] at position 471 and a cysteine [C] at position 473 or an immunologically active fragment thereof comprising the two amino acid substitutions.
An isolated and purified pore-forming toxoid of vaginolysin from G. vaginalis, which toxoid differs from vaginolysin identified by SEQ ID NO:
- 2 by a two amino acid substitutions consisting of a tryptophan [W] at position 480, and an isoleucine at position 500, or an immunologically active fragment thereof comprising the two amino acid substitutions.
Dependencies are inferred from the claim text.